About the Company
Sangamo Therapeutics, Inc. (previously known as Sangamo Biosciences, Inc.) is an American biotechnology company based in Brisbane, California. It applies cell and gene therapy to combat haemophilia and other genetic diseases.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on SANGAMO THERAPEUTICS, INC
Sangamo Therapeutics, Inc. (SGMO) Investors Who Lost Money – Contact ...
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN SANGAMO THERAPEUTICS, INC. (SGMO), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
Sangamo Therapeutics Reports Second Quarter 2019 Financial Results
BRISBANE, Calif.-- (BUSINESS WIRE)--Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported second quarter 2019 financial results and recent business highlights.
Sangamo Therapeutics Reports Recent Business Highlights and Fourth ...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported fourth quarter and full year 2020 financial results and recent b ...
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results
Detailed price information for Sangamo Therapeutics (SGMO-Q) from The Globe and Mail including charting and trades.
Here's Why Sangamo Therapeutics Inc. Stock Soared 438% in 2017
What happened Gene editing pioneer Sangamo Therapeutics Inc. (NASDAQ: SGMO) delivered a stunning 437.7% return in 2017, according to data from S&P Global Market Intelligence .
Case Western Reserve and Sangamo Therapeutics Announce $11 Million NIH ...
Case Western Reserve University and Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced the award of an $11 million grant from the National Institutes of Health for a planned study of ...
Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid ...
Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, today announced it has entered into a license agreement with Genentech, a member of the Roche Group, to develop intravenously ...
Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights ...
Positive Points Sangamo Therapeutics Inc (NASDAQ:SGMO) signed a third capsid license agreement with Eli Lilly, potentially earning up to $1.4 billion in milestone payments.
Sangamo: $665M In Cash Ready To Be Deployed Across A Pipeline Of 18 ...
Sangamo: $665M In Cash Ready To Be Deployed Across A Pipeline Of 18 Therapeutics And 2 New 2020 Partnerships, 29% Upside Oct. 06, 2020 2:25 PM ET Sangamo Therapeutics, Inc. (SGMO) Stock BIIB, NVS ...
Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights ...
Sangamo Therapeutics Inc (SGMO) reports significant progress in its Fabry disease program and neurology therapies, while navigating financial hurdles and partnership negotiations.
Sangamo Therapeutics Inc. (SGMO): This Small-Cap Stock Is Poised To ...
We recently compiled a list of the 15 Small-Cap Stocks Poised to Outperform in 2025. In this article, we are going to take a look at where Sangamo Therapeutics Inc.
Similar Companies
Loading the latest forecasts...